SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Down 17.6% in December

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the recipient of a significant decline in short interest in December. As of December 15th, there was short interest totalling 7,460,000 shares, a decline of 17.6% from the November 30th total of 9,050,000 shares. Based on an average trading volume of 978,800 shares, the days-to-cover ratio is currently 7.6 days.

Institutional Trading of SELLAS Life Sciences Group

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC acquired a new stake in shares of SELLAS Life Sciences Group during the 2nd quarter valued at $39,000. XTX Topco Ltd bought a new position in SELLAS Life Sciences Group in the third quarter valued at about $78,000. Virtu Financial LLC boosted its stake in shares of SELLAS Life Sciences Group by 24.1% during the third quarter. Virtu Financial LLC now owns 79,241 shares of the company’s stock valued at $99,000 after purchasing an additional 15,398 shares in the last quarter. State Street Corp grew its holdings in shares of SELLAS Life Sciences Group by 30.2% during the third quarter. State Street Corp now owns 174,529 shares of the company’s stock worth $218,000 after purchasing an additional 40,500 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of SELLAS Life Sciences Group by 17.1% in the third quarter. Geode Capital Management LLC now owns 605,191 shares of the company’s stock valued at $757,000 after buying an additional 88,183 shares during the period. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Price Performance

SLS stock opened at $0.99 on Tuesday. The stock has a market cap of $69.90 million, a price-to-earnings ratio of -1.44 and a beta of 2.39. The company has a 50 day simple moving average of $1.12 and a 200 day simple moving average of $1.19. SELLAS Life Sciences Group has a 1 year low of $0.50 and a 1 year high of $1.72.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.